157 related articles for article (PubMed ID: 33246428)
1. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.
Salazar R; Capdevila J; Manzano JL; Pericay C; Martínez-Villacampa M; López C; Losa F; Safont MJ; Gómez-España A; Alonso-Orduña V; Escudero P; Gallego J; García-Paredes B; Palacios A; Biondo S; Grávalos C; Aranda E;
BMC Cancer; 2020 Nov; 20(1):1164. PubMed ID: 33246428
[TBL] [Abstract][Full Text] [Related]
2. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C;
Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer.
Huang CW; Hu HM; Hsu WH; Chen CY; Huang MY; Chen CP; Wei PL; Shen BN; Wang JY
Nanomedicine (Lond); 2023 Mar; 18(6):511-524. PubMed ID: 37166053
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer.
Clifford R; Govindarajah N; Parsons JL; Gollins S; West NP; Vimalachandran D
Br J Surg; 2018 Nov; 105(12):1553-1572. PubMed ID: 30311641
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.
Bedi M; Das P; Skibber JM; Rodriguez-Bigas MA; Chang GJ; Eng C; Wolff RA; Janjan NA; Krishnan S; Crane CH
Gastrointest Cancer Res; 2007 Mar; 1(2):44-8. PubMed ID: 19262718
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw after radiation followed by bevacizumab.
Park L; Vasile G; Hensley H; Buckley C
Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762867
[TBL] [Abstract][Full Text] [Related]
7. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM
J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of metronomic chemotherapy in patients with metastatic breast cancer - an international experience in West Sweden and in the South of Ireland.
Weadick C; Larsson K; O'Reilly S; McMahon E; O'Mahony D; Linderholm BK
Cancer Treat Res Commun; 2020; 25():100237. PubMed ID: 33248390
[TBL] [Abstract][Full Text] [Related]
10. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
[TBL] [Abstract][Full Text] [Related]
11. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
12. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
Moriwaki T; Gosho M; Sugaya A; Yamada T; Yamamoto Y; Hyodo I
Cancer Res Treat; 2021 Jul; 53(3):703-713. PubMed ID: 33285056
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Yamamoto N; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Yamanaka T; Tanaka M; Takahashi K; Fukuoka M
Lung Cancer; 2021 Jan; 151():20-24. PubMed ID: 33279874
[TBL] [Abstract][Full Text] [Related]
14. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
[TBL] [Abstract][Full Text] [Related]
15. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
[TBL] [Abstract][Full Text] [Related]
16. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
Wu YL; Shi Y; Tan DSW; Xiaoqing L; Cheng Y; Zhou J; An TT; Lu Y; Zhu B; Bai C; Passos VQ; Lau YY; Xun L; Zhang L
Lung Cancer; 2020 Dec; 150():240-246. PubMed ID: 33249379
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study.
Kurilova I; Bendet A; Petre EN; Boas FE; Kaye E; Gonen M; Covey A; Brody LA; Brown KT; Kemeny NE; Yarmohammadi H; Ziv E; D'Angelica MI; Kingham TP; Cercek A; Solomon SB; Beets-Tan RGH; Sofocleous CT
Clin Colorectal Cancer; 2021 Jun; 20(2):e82-e95. PubMed ID: 33246789
[TBL] [Abstract][Full Text] [Related]
18. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z
Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647
[TBL] [Abstract][Full Text] [Related]
19. Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials.
Riesco-Martinez MC; Fernandez-Martos C; Gravalos-Castro C; Espinosa-Olarte P; La Salvia A; Robles-Diaz L; Modrego-Sanchez A; Garcia-Carbonero R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291454
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and efficacy of shorter
Lobefaro R; Zattarin E; Nichetti F; Prisciandaro M; Ligorio F; Brambilla M; Sepe P; Corti F; Peverelli G; Ottini A; Beninato T; Mazzeo L; Rea CG; Mariani G; de Braud F; Bianchi GV; Vernieri C; Capri G
Ther Adv Med Oncol; 2020; 12():1758835920970081. PubMed ID: 33335565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
